Neuroprotective effects of pramipexole in young and aged MPTP-treated mice (Q43651452)

25 November 2017

title

Neuroprotective effects of pramipexole in young and aged MPTP-treated mice (English)

1 reference

25 November 2017

Anderson DW

1

1 reference

25 November 2017

Neavin T

series ordinal

2

1 reference

25 November 2017

Smith JA

series ordinal

3

1 reference

25 November 2017

Schneider JS

series ordinal

4

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

905

1 reference

25 November 2017

issue

1-2

1 reference

25 November 2017

page(s)

44-53

1 reference

Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Pramipexole. A review of its use in the management of early and advanced Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

The oxidant stress hypothesis in Parkinson's disease: evidence supporting it

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

The etiology of Parkinson's disease with emphasis on the MPTP story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Difference in recovery patterns of striatal dopamine content, tyrosine hydroxylase activity and total biopterin content after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration: a comparison of young and older mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Attempts to obtain neuroprotection in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

An Evaluation of Cresyl Echt Violet Acetate as a Nissl Stain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Effects of age on GM1 ganglioside-induced recovery of concentrations of dopamine in the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Mitochondrial oxidative phosphorylation defects in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Mechanism of the neurotoxicity of MPTP. An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Xenobiotic metabolism in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

The role of dopamine agonists in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Do dopamine agonists provide neuroprotection?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902466-0

10.1016/S0006-8993(01)02466-0

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference